MMDA (drug)
MMDA, also known as 3-methoxy-4,5-methylenedioxyamphetamine or as 5-methoxy-MDA, is a psychedelic and entactogen of the amphetamine family.
MMDA was described by Alexander Shulgin in his book PiHKAL. Shulgin lists the dosage range of MMDA as 100 to 250mg. The first effects appear within 20 to 45minutes following oral administration. Its duration is described as "moderate".
MMDA produces effects including relaxation, time dilation, empathy, passivity, compassion, changes in music perception, closed-eye visuals such as geometric patterns, open-eye visuals, dream-like states described as "brain movies", and an afterglow. It has been said to be gentler than certain other psychedelics. The drug is said to have similar effects to MDA, but to be to some extent more psychedelic in comparison.
Side effects
Side effects of MMDA have been reported to include restlessness, cold sensations, shivering, nausea, abdominal cramps, disorientation, social withdrawal, feeling ill, and anxiety.
Pharmacology
Pharmacodynamics
MMDA has been shown to act as a non-neurotoxic serotonin releasing agent, with no effects on release of dopamine or probably norepinephrine, and as a serotonin 5-HT2A receptor agonist. The latter property is thought to be responsible for its psychedelic effects, whereas the former action may be involved in its entactogenic effects.
Pharmacokinetics
MMDA has been found to be formed from myristicin, a component of nutmeg, in rabbits and rats. However, MMDA could not be detected with nutmeg misuse in a human.
Chemistry
Analogues
Analogues of MMDA include lophophine, MDA, MDMA, and TMA. Positional isomers of MMDA include MMDA-2, MMDA-3a, MMDA-3b, MMDA-4, and MMDA-5. Further analogues and derivatives of MMDA include DMMDA, DMMDA-2, DMMDA-3, DMMDA-4, DMMDA-5, and DMMDA-6. Other analogues of MMDA include 4T-MMDA-2 and 2T-MMDA-3a.
History
MMDA was first synthesized and studied by Gordon Alles at the Edgewood Arsenal in the mid-1950s. Its Edgewood Arsenal code name is unknown. Subsequently, Alexander Shulgin synthesized MMDA in 1962 and discovered its psychoactive effects that same year. Shulgin published his findings on MMDA in the scientific literature in 1964. Use of MMDA in psychedelic-assisted psychotherapy was studied by Shulgin, Thornton Sargent, and Claudio Naranjo in the mid-1960s and their findings were published in 1973. Naranjo also described MMDA for these purposes in his 1973 book The Healing Journey: New Approaches to Consciousness. Shulgin subsequently further described MMDA in his book PiHKAL in 1991.
Society and culture
International
Internationally, MMDA is a Schedule I drug under the Convention on Psychotropic Substances.
Australia
MMDA is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard. A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Canada
MMDA is a Schedule I controlled substance in Canada.
MMDA is classified as a Schedule 1 controlled substance in the United States.